Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E

References

• Dembek ZF, Smith LA, Rusnak JM. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med Public Health Prep. 2007;1:122–34. doi:10.1097/DMP.0b013e318158c5fd.
   PubMed Web of Science ®Google Scholar
• Smith LA. Botulism and vaccines for its prevention. Vaccine. 2009;27(Suppl 4):D33–D39. doi:10.1016/j.vaccine.2009.08.059.
   PubMed Web of Science ®Google Scholar
• Sundeen G, Barbieri JT. Vaccines against Botulism. Toxins. 2017;9:268.
   Web of Science ®Google Scholar
• Shukla HD, Sharma SK. Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol. 2005;31:11–18. doi:10.1080/10408410590912952.
   PubMed Web of Science ®Google Scholar
• Rusnak JM, Smith LA. Botulinum neurotoxin vaccines: past history and recent developments. Hum Vaccin. 2009;5:794–805. doi:10.4161/hv.9420.
   PubMed Web of Science ®Google Scholar
• Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci. 2002;27:552–58.
   PubMed Web of Science ®Google Scholar
• Smith LA, Rusnak JM. Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol. 2007;27:303–18.
   PubMed Web of Science ®Google Scholar
• Schiavo G, Rossetto O, Santucci A, DasGupta BR, Montecucco C. Botulinum neurotoxins are zinc proteins. J Biol Chem. 1992;267:23479–83.
   PubMed Web of Science ®Google Scholar
• Gu S, Jin R. Assembly and function of the botulinum neurotoxin progenitor complex. Curr Top Microbiol Immunol. 2013;364:21–44. doi:10.1007/978-3-642-33570-9_2.
   PubMed Web of Science ®Google Scholar
• Lee K, Gu SY, Jin L, Le TTN, Cheng LW, Strotmeier J, Kruel AM, Yao G, Perry K, Rummel A, et al. Structure of a bimodular botulinum neurotoxin complex provides insights into its oral toxicity. PLoS Pathog. 2013;9:e1003690. doi:10.1371/journal.ppat.1003690.
   PubMed Web of Science ®Google Scholar
• Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000;80:717–66. doi:10.1152/physrev.2000.80.2.717.
   PubMed Web of Science ®Google Scholar
• Matak I, Lackovic Z. Botulinum toxin A, brain and pain. Prog Neurobiol. 2014;119–120:39–59. doi:10.1016/j.pneurobio.2014.06.001.
   PubMed Web of Science ®Google Scholar
• Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, et al. Botulinum toxin as a biological weapon – medical and public health management. Jama-J Am Med Assoc. 2001;285:1059–70. doi:10.1001/jama.285.8.1059.
   PubMed Web of Science ®Google Scholar
• Rossow H, Kinnunen PM, Nikkari S. Botulinum toxin as a biological weapon. Duodecim. 2012;128:1678–84.
   PubMedGoogle Scholar
• Pittman PR, Hack D, Mangiafico J, Gibbs P, McKee KT, Friedlander AM, Sjogren MH. Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid. Vaccine. 2002;20:2107–15.
   PubMed Web of Science ®Google Scholar
• Cieslak TJ, Christopher GW, Kortepeter MG, Rowe JR, Pavlin JA, Culpepper RC, Eitzen EM. Immunization against potential biological warfare agents. Clin Infect Dis. 2000;30:843–50. doi:10.1086/313812.
   PubMed Web of Science ®Google Scholar
• Torii Y, Tokumaru Y, Kawaguchi S, Izumi N, Maruyama S, Mukamoto M, Kozaki S, Takahashi M. Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid. Vaccine. 2002;20:2556–61.
   PubMed Web of Science ®Google Scholar
• Froude JW, Stiles B, Pelat T, Thullier P. Antibodies for biodefense. MAbs. 2011;3:517–27. doi:10.4161/mabs.3.6.17621.
   PubMed Web of Science ®Google Scholar
• Mayers CN, Holley JL, Brooks T. Antitoxin therapy for botulinum intoxication. Rev Med Microbiol. 2001;12:29–37. doi:10.1097/00013542-200101000-00004.
   Web of Science ®Google Scholar
• Yu YZ, Gong ZW, Ma Y, Zhang SM, Zhu HQ, Wang WB, Du Y, Wang S, Yu W-Y, Sun Z-W. Co-expression of tetanus toxin fragment C in Escherichia coli with thioredoxin and its evaluation as an effective subunit vaccine candidate. Vaccine. 2011;29:5978–85. doi:10.1016/j.vaccine.2011.06.039.
   PubMed Web of Science ®Google Scholar
• Moreira GM, Cunha CE, Salvarani FM, Gonçalves LA, Pires PS, Conceição FR, Lobato FC. Production of recombinant botulism antigens: a review of expression systems. Anaerobe. 2014;28:130–36. doi:10.1016/j.anaerobe.2014.06.003.
   PubMed Web of Science ®Google Scholar
• Holley JL, Elmore M, Mauchline M, Minton N, Titball RW. Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin. Vaccine. 2000;19:288–97.
   PubMed Web of Science ®Google Scholar
• Yu YZ, Li N, Wang RL, Zhu HQ, Wang S, Yu WY, Sun ZW. Evaluation of a recombinant Hc of clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Clin Vaccine Immunol. 2008;15:1819–23. doi:10.1128/CVI.00239-08.
   PubMed Web of Science ®Google Scholar
• Yu YZ, Li N, Zhu HQ, Wang RL, Du Y, Wang S, Yu W-Y, Sun Z-W. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine. 2009;27:2816–22. doi:10.1016/j.vaccine.2009.02.091.
   PubMed Web of Science ®Google Scholar
• Yunzhou Y, Danyang S, Si L, Zheng-Wei G, Shuang W, Zhiwei S. Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system. Hum Vaccin. 2015;11:468–73. doi:10.4161/hv.29714.
   Web of Science ®Google Scholar
• Liu B, Shi D, Chang S, Gong X, Yu Y, Sun Z, Wu J. Characterization and immunological activity of different forms of recombinant secreted Hc of botulinum neurotoxin serotype B products expressed in yeast. Sci Rep. 2015;5:7678. doi:10.1038/srep07678.
   PubMed Web of Science ®Google Scholar
• Yu YZ, Zhang SM, Ma Y, Zhu HQ, Wang WB, Du Y, Zhou X-W, Wang R-L, Wang S, Yu W-Y, et al. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F. Clin Immunol. 2010;137:271–80. doi:10.1016/j.clim.2010.07.005.
   PubMed Web of Science ®Google Scholar
• Shi DY, Chen BY, Mao YY, Zhou G, Lu JS, Yu YZ, Zhou XW. Development and evaluation of candidate subunit vaccine against botulinum neurotoxin serotype B. Hum Vaccin Immunother. 2019;15:755–60. doi:10.1080/21645515.2018.1547613.
   PubMed Web of Science ®Google Scholar
• Jones RG, Alsop TA, Hull R, Tierney R, Rigsby P, Holley J, Sesardic D. Botulinum type A toxin neutralisation by specific IgG and its fragments: a comparison of mouse systemic toxicity and local flaccid paralysis assays. Toxicon. 2006;48:246–54. doi:10.1016/j.toxicon.2006.05.007.
   PubMed Web of Science ®Google Scholar
• Yu YZ, Guo JP, An HJ, Zhang SM, Wang S, Yu WY, Sun ZW. Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based semliki forest virus replicon vectors. Vaccine. 2013;31:2427–32. doi:10.1016/j.vaccine.2013.03.046.
   PubMed Web of Science ®Google Scholar
• Sinha J, Inan M, Fanders S, Taoka S, Gouthro M, Swanson T, Barent R, Barthuli A, Loveless BM, Smith LA, et al. Cell bank characterization and fermentation optimization for production of recombinant heavy chain C-terminal fragment of botulinum neurotoxin serotype E (rBoNTE(Hc): antigen E) by Pichia pastoris. J Biotechnol. 2007;127:462–74. doi:10.1016/j.jbiotec.2006.07.022.
   PubMed Web of Science ®Google Scholar
• Byrne MP, Titball RW, Holley J, Smith LA. Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris. Protein Expr Purif. 2000;18:327–37. doi:10.1006/prep.2000.1200.
   PubMed Web of Science ®Google Scholar
• Bing NI, Wang XL, Wang L, Zhao GY, Shi XF, Zhang SL, Zhang LY. Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody. Immunol J. 2005;10:681–90.
   Google Scholar
• Yu YZ, Zhang SM, Wang WB, Du Y, Zhu HQ, Wang RL, Zhou X-W, Lin J-B, Wang S, Yu W-Y, et al. Development and preclinical evaluation of a new F(ab′)2 antitoxin against botulinum neurotoxin serotype A. Biochimie. 2010;92:1315–20. doi:10.1016/j.biochi.2010.06.010.
   PubMed Web of Science ®Google Scholar
• Kittipongwarakarn S, Hawe A, Tantipolphan R, Limsuwun K, Khomvilai S, Puttipipatkhachorn S, Jiskoot W. New method to produce equine antirabies immunoglobulin F(ab’)2 fragments from crude plasma in high quality and yield. Eur J Pharm Biopharm. 2011;78:189–95. doi:10.1016/j.ejpb.2011.02.018.
   PubMed Web of Science ®Google Scholar
• Morais V, Massaldi H. Effect of pepsin digestion on the antivenom activity of equine immunoglobulins. Toxicon. 2005;46:876–82. doi:10.1016/j.toxicon.2005.08.006.
   PubMed Web of Science ®Google Scholar
• Rial A, Morais V, Rossi S, Massaldi H. A new ELISA for determination of potency in snake antivenoms. Toxicon. 2006;48:462–66. doi:10.1016/j.toxicon.2006.07.004.
   PubMed Web of Science ®Google Scholar